Please use this identifier to cite or link to this item: doi:10.22028/D291-30169
Title: Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer
Author(s): Meyer, Felix
Becker, Saskia
Classen, Sandra
Parplys, Ann Christin
Mansour, Wael Yassin
Riepen, Britta
Timm, Sara
Ruebe, Claudia
Jasin, Maria
Wikman, Harriet
Petersen, Cordula
Rothkamm, Kai
Borgmann, Kerstin
Language: English
Title: Cells
Volume: 9
Issue: 1
Publisher/Platform: MDPI
Year of Publication: 2020
Free key words: triple-negative breast cancer (TNBC)
chromosomal instability (CIN)
CIN70 score
homologous recombination (HR)
DNA-damage response (DDR)
CHK1
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Chromosomal instability not only has a negative effect on survival in triple-negative breast cancer, but also on the well treatable subgroup of luminal A tumors. This suggests a general mechanism independent of subtypes. Increased chromosomal instability (CIN) in triple-negative breast cancer (TNBC) is attributed to a defect in the DNA repair pathway homologous recombination. Homologous recombination (HR) prevents genomic instability by repair and protection of replication. It is unclear whether genetic alterations actually lead to a repair defect or whether superior signaling pathways are of greater importance. Previous studies focused exclusively on the repair function of HR. Here, we show that the regulation of HR by the intra-S-phase damage response at the replication is of overriding importance. A damage response activated by Ataxia telangiectasia and Rad3 related-checkpoint kinase 1 (ATR-CHK1) can prevent replication stress and leads to resistance formation. CHK1 thus has a preferred role over HR in preventing replication stress in TNBC. The signaling cascade ATR-CHK1 can compensate for a double-strand break repair error and lead to resistance of HR-deficient tumors. Established methods for the identification of HR-deficient tumors for Poly(ADP-Ribose)-Polymerase 1 (PARP1) inhibitor therapies should be extended to include analysis of candidates for intra-S phase damage response.
DOI of the first publication: 10.3390/cells9010238
Link to this record: urn:nbn:de:bsz:291--ds-301698
hdl:20.500.11880/30174
http://dx.doi.org/10.22028/D291-30169
ISSN: 2073-4409
Date of registration: 9-Dec-2020
Description of the related object: Supplementary Materials
Related object: http://www.mdpi.com/2073-4409/9/1/238/s1
Faculty: M - Medizinische Fakultät
Department: M - Radiologie
Professorship: M - Keiner Professur zugeordnet
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
cells-09-00238.pdf2,99 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons